Key Points
-
Neutralizing antibodies are the means by which most viral vaccines protect against infection or disease, including the successful subunit influenza virus vaccine.
-
Influenza virus and HIV-1 are both highly variable, globally persistent viruses. HIV-1 causes a chronic infection, as the virus continually evolves to escape host immune responses in each infected individual. Influenza virus causes an acute infection and the virus escapes host neutralizing antibodies that were elicited by previous infection or vaccination by infecting new individuals with no or low pre-existing immunity.
-
Despite the differences in how HIV-1 and influenza virus achieve global persistence, parallels can be drawn between the two viruses in regards to the challenge to elicit neutralizing antibodies against these viruses. Both viruses possess envelope glycoproteins (Envs) of similar architecture and entry-related functions that are the sole viral targets for neutralizing antibodies. For both viruses, the Envs have evolved immunogenic variable regions to divert the immune response and N-linked glycans to shield the virus from neutralizing antibodies.
-
Seasonal influenza virus vaccine production currently relies on predictions of the most likely emerging strains in a given year and, if a match to circulating virus is achieved, the vaccine is highly protective. However, for pandemic influenza virus, or avian 'flu, greater vaccine challenges related to viral diversity are faced, as it is difficult to predict which influenza virus strain may cross to the human population from the broad array of isolates that circulate in avian reservoirs.
-
Strategies to develop influenza virus vaccines that are more crossreactive and more immunogenic are therefore needed. These would have minimal requirements that are similar to those of an HIV-1 vaccine, which needs to induce crossprotective broadly neutralizing antibodies.
-
For HIV-1, structure-guided immunogen-design efforts that are based on rational re-engineering of recombinant Envs are in development. These are aimed at improving the presentation of conserved, broadly neutralizing B-cell epitopes to the immune system to better elicit broad neutralizing responses.
-
Similarities exist in the challenges of developing vaccines that induce broadly neutralizing antibodies against HIV-1 and influenza virus, which suggests that the two fields may benefit from increased exchange of approaches and concepts in regards to the elicitation of such broad responses.
Abstract
The ability to elicit broadly neutralizing antibody responses against HIV-1 is a crucial goal for a prophylactic HIV-1 vaccine. Here, we discuss the difficulties of achieving broad HIV-1 neutralization in the context of both the effective annual human influenza virus vaccine and the need to develop a pandemic influenza vaccine. Immunogen-design strategies are underway to target functionally conserved regions of the HIV-1 envelope glycoproteins, and similar strategies might be applicable to pandemic influenza virus vaccine development. Efforts to develop broadly neutralizing vaccines against either HIV-1 or influenza virus might establish a paradigm for future vaccines against highly variable pathogens.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$259.00 per year
only $21.58 per issue
Buy this article
- Purchase on SpringerLink
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout





Similar content being viewed by others
References
Pantaleo, G. & Koup, R. A. Correlates of immune protection in HIV-1 infection: what we know, what we don't know, what we should know. Nature Med. 10, 806–810 (2004).
Plotkin, S. A. Immunologic correlates of protection induced by vaccination. Pediatr. Infect. Dis. J. 20, 63–75 (2001).
Davenport, M. P., Ribeiro, R. M., Chao, D. L. & Perelson, A. S. Predicting the impact of a nonsterilizing vaccine against human immunodeficiency virus. J. Virol. 78, 11340–11351 (2004).
Subbarao, K. & Joseph, T. Scientific barriers to developing vaccines against avian influenza viruses. Nature Rev. Immunol. 7, 267–278 (2007).
Claas, E. C. et al. Human influenza A H5N1 virus related to a highly pathogenic avian influenza virus. Lancet 351, 472–477 (1998).
de Jong, M. D. et al. Fatal avian influenza A (H5N1) in a child presenting with diarrhea followed by coma. N. Engl. J. Med. 352, 686–691 (2005).
Subbarao, K. et al. Characterization of an avian influenza A (H5N1) virus isolated from a child with a fatal respiratory illness. Science 279, 393–396 (1998).
Tran, T. H. et al. Avian influenza A (H5N1) in 10 patients in Vietnam. N. Engl. J. Med. 350, 1179–1188 (2004).
Douek, D. C., Kwong, P. D. & Nabel, G. J. The rational design of an AIDS vaccine. Cell 124, 677–681 (2006).
Burton, D. R. et al. HIV vaccine design and the neutralizing antibody problem. Nature Immunol. 5, 233–236 (2004).
Johnson, W. E. & Desrosiers, R. C. Viral persistance: HIV's strategies of immune system evasion. Annu. Rev. Med. 53, 499–518 (2002).
Kwong, P. D. et al. HIV-1 evades antibody-mediated neutralization through conformational masking of receptor-binding sites. Nature 420, 678–682 (2002).
Wyatt, R. & Sodroski, J. The HIV-1 envelope glycoproteins: fusogens, antigens, and immunogens. Science 280, 1884–1888 (1998).
Frost, S. D. et al. Neutralizing antibody responses drive the evolution of human immunodeficiency virus type 1 envelope during recent HIV infection. Proc. Natl Acad. Sci. USA 102, 18514–18519 (2005). This is a comprehensive and informative longitudinal study demonstrating that antibody responses are important for driving HIV-1 evolution in infected individuals.
Smith, D. J. et al. Mapping the antigenic and genetic evolution of influenza virus. Science 305, 371–376 (2004). Describes the antigenic evolution of influenza A (H3N2) virus from its introduction into humans in 1968 to 2003, providing an important illustration of antigenic drift.
Webster, R. G., Bean, W. J., Gorman, O. T., Chambers, T. M. & Kawaoka, Y. Evolution and ecology of influenza A viruses. Microbiol. Rev. 56, 152–179 (1992).
Wei, X. et al. Antibody neutralization and escape by HIV-1. Nature 422, 307–312 (2003).
Wendler, I., Bienzle, U. & Hunsmann, G. Neutralizing antibodies and the course of HIV-induced disease. AIDS Res. Hum. Retroviruses 3, 157–163 (1987).
Sagar, M., Kirkegaard, E., Lavreys, L. & Overbaugh, J. Diversity in HIV-1 envelope V1–V3 sequences early in infection reflects sequence diversity throughout the HIV-1 genome but does not predict the extent of sequence diversity during chronic infection. AIDS Res. Hum. Retroviruses 22, 430–437 (2006).
Sagar, M., Wu, X., Lee, S. & Overbaugh, J. Human immunodeficiency virus type 1 V1–V2 envelope loop sequences expand and add glycosylation sites over the course of infection, and these modifications affect antibody neutralization sensitivity. J. Virol. 80, 9586–9598 (2006).
Li, M. et al. Human immunodeficiency virus type 1 env clones from acute and early subtype B infections for standardized assessments of vaccine-elicited neutralizing antibodies. J. Virol. 79, 10108–10125 (2005).
Burton, D. R., Stanfield, R. L. & Wilson, I. A. Antibody vs. HIV in a clash of evolutionary titans. Proc. Natl Acad. Sci. USA 102, 14943–14948 (2005).
Eisen, M. B., Sabesan, S., Skehel, J. J. & Wiley, D. C. Binding of the influenza A virus to cell-surface receptors: structures of five hemagglutinin–sialyloligosaccharide complexes determined by X-ray crystallography. Virology 232, 19–31 (1997).
Sauter, N. K. et al. Binding of influenza virus hemagglutinin to analogs of its cell-surface receptor, sialic acid: analysis by proton nuclear magnetic resonance spectroscopy and X-ray crystallography. Biochemistry 31, 9609–9621 (1992).
Watowich, S. J., Skehel, J. J. & Wiley, D. C. Crystal structures of influenza virus hemagglutinin in complex with high-affinity receptor analogs. Structure 2, 719–731 (1994).
Wiley, D. C. & Skehel, J. J. The structure and function of the hemagglutinin membrane glycoprotein of influenza virus. Annu. Rev. Biochem. 56, 365–394 (1987).
Wiley, D. C., Wilson, I. A. & Skehel, J. J. Structural identification of the antibody-binding sites of Hong Kong influenza haemagglutinin and their involvement in antigenic variation. Nature 289, 373–378 (1981).
Wilson, I. A. & Cox, N. J. Structural basis of immune recognition of influenza virus hemagglutinin. Annu. Rev. Immunol. 8, 737–771 (1990).
Alexander, S. & Elder, J. H. Carbohydrate dramatically influences immune reactivity of antisera to viral glycoprotein antigens. Science 226, 1328–1330 (1984).
Vigerust, D. J. et al. N-Linked glycosylation attenuates H3N2 influenza viruses. J. Virol. 81, 8593–8600 (2007).
Barbey-Martin, C. et al. An antibody that prevents the hemagglutinin low pH fusogenic transition. Virology 294, 70–74 (2002).
Bizebard, T. et al. Structure of influenza virus haemagglutinin complexed with a neutralizing antibody. Nature 376, 92–94 (1995).
Fleury, D. et al. A complex of influenza hemagglutinin with a neutralizing antibody that binds outside the virus receptor binding site. Nature Struct. Biol. 6, 530–534 (1999).
Chen, B. et al. Structure of an unliganded simian immunodeficiency virus gp120 core. Nature 433, 834–841 (2005).
Kwong, P. D., Wyatt, R., Sattentau, Q. J., Sodroski, J. & Hendrickson, W. A. Oligomeric modeling and electrostatic analysis of the gp120 envelope glycoprotein of human immunodeficiency virus. J. Virol. 74, 1961–1972 (2000).
Javaherian, K. et al. Broadly neutralizing antibodies elicited by the hypervariable neutralizing determinant of HIV-1. Science 250, 1590–1593 (1990).
Zwart, G. et al. Immunodominance and antigenic variation of the principal neutralization domain of HIV-1. Virology 181, 481–489 (1991).
Hartley, O., Klasse, P. J., Sattentau, Q. J. & Moore, J. P. V3: HIV's switch-hitter. AIDS Res. Hum. Retroviruses 21, 171–189 (2005).
Huang, C. C. et al. Structure of a V3-containing HIV-1 gp120 core. Science 310, 1025–1028 (2005).
McKnight, A. et al. Change in tropism upon immune escape by human immunodeficiency virus. J. Virol. 69, 3167–3170 (1995).
Knossow, M. et al. Mechanism of neutralization of influenza virus infectivity by antibodies. Virology 302, 294–298 (2002).
Beyer, W. E., Palache, A. M., de Jong, J. C. & Osterhaus, A. D. Cold-adapted live influenza vaccine versus inactivated vaccine: systemic vaccine reactions, local and systemic antibody response, and vaccine efficacy. A meta-analysis. Vaccine 20, 1340–1353 (2002).
Abramson, J. S. Intranasal, cold-adapted, live, attenuated influenza vaccine. Pediatr. Infect. Dis. J. 18, 1103–1104 (1999).
Longini, I. M. et al. Estimation of the efficacy of live, attenuated influenza vaccine from a two-year, multi-center vaccine trial: implications for influenza epidemic control. Vaccine 18, 1902–1909 (2000).
Mendelman, P. M., Cordova, J. & Cho, I. Safety, efficacy and effectiveness of the influenza virus vaccine, trivalent, types A and B, live, cold-adapted (CAIV-T) in healthy children and healthy adults. Vaccine 19, 2221–2226 (2001).
Subbarao, K., Murphy, B. R. & Fauci, A. S. Development of effective vaccines against pandemic influenza. Immunity 24, 5–9 (2006).
Doherty, P. C., Turner, S. J., Webby, R. G. & Thomas, P. G. Influenza and the challenge for immunology. Nature Immunol. 7, 449–455 (2006).
Palese, P. Making better influenza virus vaccines? Emerg. Infect. Dis. 12, 61–65 (2006).
Leroux-Roels, I. et al. Antigen sparing and cross-reactive immunity with an adjuvanted rH5N1 prototype pandemic influenza vaccine: a randomised controlled trial. Lancet 370, 580–589 (2007). Provides compelling data that supports the use of adjuvants as an antigen-sparing strategy for recombinant H5N1 split-virion vaccines.
de Wit, E. et al. Protection of mice against lethal infection with highly pathogenic H7N7 influenza A virus by using a recombinant low-pathogenicity vaccine strain. J. Virol. 79, 12401–12407 (2005).
Govorkova, E. A., Webby, R. J., Humberd, J., Seiler, J. P. & Webster, R. G. Immunization with reverse-genetics-produced H5N1 influenza vaccine protects ferrets against homologous and heterologous challenge. J. Infect. Dis. 194, 159–167 (2006).
Webster, R. G. et al. The immunogenicity and efficacy against H5N1 challenge of reverse genetics-derived H5N3 influenza vaccine in ducks and chickens. Virology 351, 303–311 (2006).
Rimmelzwaan, G. F., Baars, M., van Amerongen, G., van Beek, R. & Osterhaus, A. D. A single dose of an ISCOM influenza vaccine induces long-lasting protective immunity against homologous challenge infection but fails to protect Cynomolgus macaques against distant drift variants of influenza A (H3N2) viruses. Vaccine 20, 158–163 (2001).
Webby, R. J. et al. Responsiveness to a pandemic alert: use of reverse genetics for rapid development of influenza vaccines. Lancet 363, 1099–1103 (2004).
Epstein, S. L. et al. Protection against multiple influenza A subtypes by vaccination with highly conserved nucleoprotein. Vaccine 23, 5404–5410 (2005).
Tompkins, S. M. et al. Matrix protein 2 vaccination and protection against influenza viruses, including subtype H5N1. Emerg. Infect. Dis. 13, 426–435 (2007).
Gao, W. et al. Protection of mice and poultry from lethal H5N1 avian influenza virus through adenovirus-based immunization. J. Virol. 80, 1959–1964 (2006).
Hoelscher, M. A. et al. Development of adenoviral-vector-based pandemic influenza vaccine against antigenically distinct human H5N1 strains in mice. Lancet 367, 475–481 (2006).
Kodihalli, S. et al. DNA vaccine encoding hemagglutinin provides protective immunity against H5N1 influenza virus infection in mice. J. Virol. 73, 2094–2098 (1999).
Kong, W. P. et al. Protective immunity to lethal challenge of the 1918 pandemic influenza virus by vaccination. Proc. Natl Acad. Sci. USA 103, 15987–15991 (2006).
Kreijtz, J. H. et al. Recombinant modified vaccinia virus Ankara-based vaccine induces protective immunity in mice against infection with influenza virus H5N1. J. Infect. Dis. 195, 1598–1606 (2007).
Qiu, M. et al. Protection against avian influenza H9N2 virus challenge by immunization with hemagglutinin- or neuraminidase-expressing DNA in BALB/c mice. Biochem. Biophys. Res. Commun. 343, 1124–1131 (2006).
Sandbulte, M. R. et al. Cross-reactive neuraminidase antibodies afford partial protection against H5N1 in mice and are present in unexposed humans. PLoS Med. 4, e59 (2007).
Shi, L. et al. GARDASIL: prophylactic human papillomavirus vaccine development—from bench top to bed-side. Clin. Pharmacol. Ther. 81, 259–264 (2007).
Li, Y. et al. Broad HIV-1 neutralization mediated by CD4-binding site antibodies. Nature Med. 13, 1032–1034 (2007). Demonstrates, for the first time, that broadly neutralizing activity in HIV-1 polyclonal patient sera is mediated by antibodies that recognize the CD4 binding site of gp120.
Albrecht, H. Making sense of AIDSVAX. AIDS Clin. Care 15, 42 (2003).
Phogat, S. & Wyatt, R. Rational modifications of HIV-1 envelope glycoproteins for immunogen design. Curr. Pharm. Des. 13, 213–227 (2007).
Haynes, B. F. & Montefiori, D. C. Aiming to induce broadly reactive neutralizing antibody responses with HIV-1 vaccine candidates. Expert Rev. Vaccines 5, 347–363 (2006).
Lu, S. Combination DNA plus protein HIV vaccines. Semin. Immunopathol. 28, 255–265 (2006).
Pantophlet, R. & Burton, D. R. GP120: target for neutralizing HIV-1 antibodies. Annu. Rev. Immunol. 24, 739–769 (2006).
Scanlan, C. N., Offer, J., Zitzmann, N. & Dwek, R. A. Exploiting the defensive sugars of HIV-1 for drug and vaccine design. Nature 446, 1038–1045 (2007).
Srivastava, I. K., Ulmer, J. B. & Barnett, S. W. Role of neutralizing antibodies in protective immunity against HIV. Hum. Vaccin. 1, 45–60 (2005).
Burton, D. R. et al. Efficient neutralization of primary isolates of HIV-1 by a recombinant human monoclonal antibody. Science 266, 1024–1027 (1994).
Olshevsky, U. et al. Identification of individual human immunodeficiency virus type 1 gp120 amino acids important for CD4 receptor binding. J. Virol. 64, 5701–5707 (1990).
Thali, M. et al. Characterization of a discontinuous human immunodeficiency virus type 1 gp120 epitope recognized by a broadly reactive neutralizing human monoclonal antibody. J. Virol. 65, 6188–6193 (1991).
Kwong, P. D. et al. Structure of an HIV gp120 envelope glycoprotein in complex with the CD4 receptor and a neutralizing human antibody. Nature 393, 648–659 (1998). This paper was a turning point for structure-based HIV-1 vaccine design, as it was the first high-resolution snapshot of the exterior Env gp120. Also see reference 84, which describes an antigenic analysis of gp120 in the context of the structure.
Zhou, T. et al. Structural definition of a conserved neutralization epitope on HIV-1 gp120. Nature 445, 732–737 (2007).
Dey, B. et al. Characterization of human immunodeficiency virus type 1 monomeric and trimeric gp120 glycoproteins stabilized in the CD4-bound state: antigenicity, biophysics, and immunogenicity. J. Virol. 81, 5579–5593 (2007).
Xiang, S. H. et al. Mutagenic stabilization and/or disruption of a CD4-bound state reveals distinct conformations of the human immunodeficiency virus type 1 gp120 envelope glycoprotein. J. Virol. 76, 9888–9899 (2002).
Myszka, D. G. et al. Energetics of the HIV gp120-CD4 binding reaction. Proc. Natl Acad. Sci. USA 97, 9026–9031 (2000).
Pantophlet, R., Wilson, I. A. & Burton, D. R. Hyperglycosylated mutants of human immunodeficiency virus (HIV) type 1 monomeric gp120 as novel antigens for HIV vaccine design. J. Virol. 77, 5889–5901 (2003).
Selvarajah, S. et al. Comparing antigenicity and immunogenicity of engineered gp120. J. Virol. 79, 12148–12163 (2005).
Leonard, C. K. et al. Assignment of intrachain disulfide bonds and characterization of potential glycosylation sites of the type 1 recombinant human immunodeficiency virus envelope glycoprotein (gp120) expressed in Chinese hamster ovary cells. J. Biol. Chem. 265, 10373–10382 (1990).
Wyatt, R. et al. The antigenic structure of the HIV gp120 envelope glycoprotein. Nature 393, 705–711 (1998).
Trkola, A. et al. Human monoclonal antibody 2G12 defines a distinctive neutralization epitope on the gp120 glycoprotein of human immunodeficiency virus type 1. J. Virol. 70, 1100–1108 (1996).
Calarese, D. A. et al. Antibody domain exchange is an immunological solution to carbohydrate cluster recognition. Science 300, 2065–2071 (2003).
Lee, S. J. et al. Mannose receptor-mediated regulation of serum glycoprotein homeostasis. Science 295, 1898–1901 (2002).
Zolla-Pazner, S. Improving on nature: focusing the immune response on the V3 loop. Hum. Antibodies 14, 69–72 (2005).
Gorny, M. K. et al. Human monoclonal antibodies specific for conformation-sensitive epitopes of V3 neutralize human immunodeficiency virus type 1 primary isolates from various clades. J. Virol. 76, 9035–9045 (2002).
Binley, J. M. et al. Comprehensive cross-clade neutralization analysis of a panel of anti-human immunodeficiency virus type 1 monoclonal antibodies. J. Virol. 78, 13232–13252 (2004).
Labrijn, A. F. et al. Access of antibody molecules to the conserved coreceptor binding site on glycoprotein gp120 is sterically restricted on primary human immunodeficiency virus type 1. J. Virol. 77, 10557–10565 (2003).
Decker, J. M. et al. Antigenic conservation and immunogenicity of the HIV coreceptor binding site. J. Exp. Med. 201, 1407–1419 (2005).
Fouts, T. et al. Crosslinked HIV-1 envelope-CD4 receptor complexes elicit broadly cross- reactive neutralizing antibodies in rhesus macaques. Proc. Natl Acad. Sci. USA 99, 11842–11847 (2002).
Muster, T. et al. A conserved neutralizing epitope on gp41 of human immunodeficiency virus type 1. J. Virol. 67, 6642–6647 (1993).
Stiegler, G. et al. A potent cross-clade neutralizing human monoclonal antibody against a novel epitope on gp41 of human immunodeficiency virus type 1. AIDS Res. Hum. Retroviruses 17, 1757–1765 (2001).
Zwick, M. B. et al. Broadly neutralizing antibodies targeted to the membrane-proximal external region of human immunodeficiency virus type 1 glycoprotein gp41. J. Virol. 75, 10892–10905 (2001).
Salzwedel, K., West, J. T. & Hunter, E. A conserved tryptophan-rich motif in the membrane-proximal region of the human immunodeficiency virus type 1 gp41 ectodomain is important for Env-mediated fusion and virus infectivity. J. Virol. 73, 2469–2480 (1999).
Ofek, G. et al. Structure and mechanistic analysis of the anti-human immunodeficiency virus type 1 antibody 2F5 in complex with its gp41 epitope. J. Virol. 78, 10724–10737 (2004).
Cardoso, R. M. et al. Broadly neutralizing anti-HIV antibody 4E10 recognizes a helical conformation of a highly conserved fusion-associated motif in gp41. Immunity 22, 163–173 (2005).
Brunel, F. M. et al. Structure-function analysis of the epitope for 4E10, a broadly neutralizing human immunodeficiency virus type 1 antibody. J. Virol. 80, 1680–1687 (2006).
McGaughey, G. B. et al. HIV-1 vaccine development: constrained peptide immunogens show improved binding to the anti-HIV-1 gp41 MAb. Biochemistry 42, 3214–3223 (2003).
Gupta, R. K. & Siber, G. R. Adjuvants for human vaccines—current status, problems and future prospects. Vaccine 13, 1263–1276 (1995).
Kenney, R. T. & Edelman, R. Survey of human-use adjuvants. Expert Rev. Vaccines 2, 167–188 (2003).
Ott, G. et al. MF59. Design and evaluation of a safe and potent adjuvant for human vaccines. Pharm. Biotechnol. 6, 277–296 (1995).
Giannini, S. L. et al. Enhanced humoral and memory B cellular immunity using HPV16/18 L1 VLP vaccine formulated with the MPL/aluminium salt combination (AS04) compared to aluminium salt only. Vaccine 24, 5937–5949 (2006).
Weiner, G. J., Liu, H. M., Wooldridge, J. E., Dahle, C. E. & Krieg, A. M. Immunostimulatory oligodeoxynucleotides containing the CpG motif are effective as immune adjuvants in tumor antigen immunization. Proc. Natl Acad. Sci. USA 94, 10833–10837 (1997).
Verthelyi, D. et al. CpG oligodeoxynucleotides as vaccine adjuvants in primates. J. Immunol. 168, 1659–1663 (2002).
Wille-Reece, U. et al. Toll-like receptor agonists influence the magnitude and quality of memory T cell responses after prime-boost immunization in nonhuman primates. J. Exp. Med. 203, 1249–1258 (2006).
Wille-Reece, U., Wu, C. Y., Flynn, B. J., Kedl, R. M. & Seder, R. A. Immunization with HIV-1 Gag protein conjugated to a TLR7/8 agonist results in the generation of HIV-1 Gag-specific TH1 and CD8+ T cell responses. J. Immunol. 174, 7676–7683 (2005).
McCormack, S. et al. A phase I trial in HIV negative healthy volunteers evaluating the effect of potent adjuvants on immunogenicity of a recombinant gp120W61D derived from dual tropic R5X4 HIV-1ACH320. Vaccine 18, 1166–1177 (2000).
Skeiky, Y. A. et al. Differential immune responses and protective efficacy induced by components of a tuberculosis polyprotein vaccine, Mtb72F, delivered as naked DNA or recombinant protein. J. Immunol. 172, 7618–7628 (2004).
Morein, B., Sundquist, B., Hoglund, S., Dalsgaard, K. & Osterhaus, A. Iscom, a novel structure for antigenic presentation of membrane proteins from enveloped viruses. Nature 308, 457–460 (1984).
Drane, D., Gittleson, C., Boyle, J. & Maraskovsky, E. ISCOMATRIX adjuvant for prophylactic and therapeutic vaccines. Expert Rev. Vaccines 6, 761–772 (2007).
Okuno, Y., Isegawa, Y., Sasao, F. & Ueda, S. A common neutralizing epitope conserved between the hemagglutinins of influenza A virus H1 and H2 strains. J. Virol. 67, 2552–2558 (1993).
World Health Organization. Antigenic and genetic characteristics of H5N1 viruses and candidate H5N1 vaccine viruses developed for potential use as pre-pandemic Vaccines [online] (2007).
Kuiken, C. L. & Goudsmit, J. Silent mutation pattern in V3 sequences distinguishes virus according to risk group in Europe. AIDS Res. Hum. Retroviruses 10, 319–320 (1994).
Skehel, J. J. & Wiley, D. C. Receptor binding and membrane fusion in virus entry: the influenza hemagglutinin. Annu. Rev. Biochem. 69, 531–569 (2000).
Fouchier, R. A. et al. Characterization of a novel influenza A virus hemagglutinin subtype (H16) obtained from black-headed gulls. J. Virol. 79, 2814–2822 (2005).
Klenk, H. D., Rott, R. & Orlich, M. Further studies on the activation of influenza virus by proteolytic cleavage of the haemagglutinin. J. Gen. Virol. 36, 151–161 (1977).
Klenk, H. D., Rott, R., Orlich, M. & Blodorn, J. Activation of influenza A viruses by trypsin treatment. Virology 68, 426–439 (1975).
Lazarowitz, S. G. & Choppin, P. W. Enhancement of the infectivity of influenza A and B viruses by proteolytic cleavage of the hemagglutinin polypeptide. Virology 68, 440–454 (1975).
Wilson, I. A., Skehel, J. J. & Wiley, D. C. Structure of the haemagglutinin membrane glycoprotein of influenza virus at 3 Å resolution. Nature 289, 366–373 (1981). This landmark paper is the first report of the structure of trimeric influenza virus HA, an achievement that was, in retrospective, ahead of its time. Also see reference 27, which describes an antigenic analysis of HA in the context of the structure.
Olofsson, S. & Bergstrom, T. Glycoconjugate glycans as viral receptors. Ann. Med. 37, 154–172 (2005).
Rogers, G. N. & D'Souza, B. L. Receptor binding properties of human and animal H1 influenza virus isolates. Virology 173, 317–322 (1989).
Rogers, G. N. & Paulson, J. C. Receptor determinants of human and animal influenza virus isolates: differences in receptor specificity of the H3 hemagglutinin based on species of origin. Virology 127, 361–373 (1983).
Yang, X., Kurteva, S., Ren, X., Lee, S. & Sodroski, J. Stoichiometry of envelope glycoprotein trimers in the entry of human immunodeficiency virus type 1. J. Virol. 79, 12132–12147 (2005).
Zhang, P. F. et al. Extensively cross-reactive anti-HIV-1 neutralizing antibodies induced by gp140 immunization. Proc. Natl Acad. Sci. USA 104, 10193–10198 (2007).
Doan, L. X., Li, M., Chen, C. & Yao, Q. Virus-like particles as HIV-1 vaccines. Rev. Med. Virol. 15, 75–88 (2005).
Fouts, T. R. et al. Expression and characterization of a single-chain polypeptide analogue of the human immunodeficiency virus type 1 gp120-CD4 receptor complex. J. Virol. 74, 11427–11436 (2000).
Varadarajan, R. et al. Characterization of gp120 and its single-chain derivatives, gp120-CD4D12 and gp120-M9: implications for targeting the CD4i epitope in human immunodeficiency virus vaccine design. J. Virol. 79, 1713–1723 (2005).
Li, M. et al. Genetic and neutralization properties of subtype C human immunodeficiency virus type 1 molecular env clones from acute and early heterosexually acquired infections in Southern Africa. J. Virol. 80, 11776–11790 (2006).
Mascola, J. R. et al. Recommendations for the design and use of standard virus panels to assess neutralizing antibody responses elicited by candidate human immunodeficiency virus type 1 vaccines. J. Virol. 79, 10103–10107 (2005).
Zhang, M. et al. Tracking global patterns of N-linked glycosylation site variation in highly variable viral glycoproteins: HIV, SIV, and HCV envelopes and influenza hemagglutinin. Glycobiology 14, 1229–1246 (2004).
Zhu, P. et al. Distribution and three-dimensional structure of AIDS virus envelope spikes. Nature 441, 847-852 (2006).
Harris, A. et al. Influenza virus pleiomorphy characterized by cryoelectron tomography. Proc. Natl Acad. Sci. USA 103, 19123–19127 (2006).
Acknowledgements
We thank B. Hartman and M. Cichanowski at the Vaccine Research Center/National Institutes of Health for expert assistance with figures. G.K.H. is supported by grants from International AIDS Vaccine Initiative (IAVI), the Swedish International Development Agency (Sida)/Department of Research Cooperation (SAREC) and the Swedish Research Council. R.F. is supported by EU FP6, an NIH contract and the Netherlands Influenza Vaccine Research Centre (ZonMW). R.T.W. and S.P. are supported by the National Institute of Allergy and Infectious Diseases (NIAID) intramural research program, IAVI and the Bill and Melinda Gates Foundation. D.B. is supported by grants from NIH and IAVI, and J.S. is supported by grants from NIH, IAVI, the Bristol–Myers Squibb Foundation, The William A. Haseltine Foundation for the Arts and Sciences and the late William F. McCarty-Cooper.
Author information
Authors and Affiliations
Corresponding author
Glossary
- Fab fragment
-
A fragment of an immunoglobulin that is formed when the molecule is digested with papain. The Fab fragment contains one complete light chain, part of a heavy chain and a single antigen-binding site.
- Adjuvant
-
An agent that is mixed with an antigen and increases the immune response to that antigen following immunization.
- TH2-biased immune response
-
The response that occurs when the cellular immune response is mainly composed of TH2 cells. There are two effector subsets of CD4+ T cells, TH1 and TH2 cells. These are characterized by distinct cytokine profiles and by functional activity. TH2 cells produce interleukin-4 (IL-4), IL-5, IL-9, IL-10, and IL-13, leading to activation of humoral immune responses. By contrast, TH1 cells produce interferon-γ, IL-2 and lymphotoxin, which support cell-mediated immunity. Appropriate differentiation of T cells into these subsets is important for mounting immune responses to pathogens, whereas an imbalance between these subsets is associated with diseases.
Rights and permissions
About this article
Cite this article
Karlsson Hedestam, G., Fouchier, R., Phogat, S. et al. The challenges of eliciting neutralizing antibodies to HIV-1 and to influenza virus. Nat Rev Microbiol 6, 143–155 (2008). https://doi.org/10.1038/nrmicro1819
Issue date:
DOI: https://doi.org/10.1038/nrmicro1819
This article is cited by
-
Assessing the human immune response to SARS-CoV-2 variants
Nature Medicine (2021)
-
In vivo delivery of a multiepitope peptide and Nef protein using novel cell-penetrating peptides for development of HIV-1 vaccine candidate
Biotechnology Letters (2021)
-
Molecular recognition of the native HIV-1 MPER revealed by STED microscopy of single virions
Nature Communications (2019)